Most viewed: Breast cancer

ENG

monarchE, KEYNOTE-522, KEYNOTE-756, CheckMate 7FL

ESMO 2023

Highlights in eBC

Giuseppe Curigliano, MD

ENG

monarchE

ESMO 2023

5 year follow-up

Nadia Harbeck, MD, PhD

USA

DESTINY-Breast-01, -02, -03

ESMO 2023

Remarkable efficacies in patients with HER2+ mBC with…

Hope Rugo, MD

USA

CheckMate 7FL

ESMO 2023

Preoperative checkpointinihition in ER+ disease

Sara Tolaney, MD

ENG

TROPION-Breast01, DESTINY-Breast-01, -02, 03, IMPACT

ESMO 2023

My highlights of ESMO23 in metastatic breast cancer

Fatima Cardoso, MD

ENG

BEGONIA, TROPION-01 Breast

ESMO 2023

DATO-DX - where is it going?

Karen Gelmon, MD

Most viewed: GU cancers

ENG

EV-302/KEYNOTE-A39

ESMO 2023

When the history of ADC is written: Redefining…

Ignacio Duran, MD

ENG

EMBARK

ESMO 2023

Early use of enzalutamide in advanced prostate cancer

Axel S. Merseburger, MD

USA

RENOTORCH

ESMO 2023

Clearing up non-clear cell RCC

Sumanta K. Pal, MD

ENG

LITESPARK-005

ESMO 2023

New 3rd line therapy for RCC

Marc-Oliver Grimm, MD

ENG

THOR, THOR-2

ESMO 2023

The FGFR story in bladder cancer at ESMO23

Yohann Loriot, MD

AUS

PSMAfore, ENZA-p

ESMO 2023

Lu-PSMA leads forward

Declan Murphy, MD

Most viewed: Lung cancer

USA

ALINA

ESMO 2023

ALINA - immediate change of practice!

Stephen Liu, MD

ENG

PAPILLON

ESMO 2023

Amivantamab as a new SoC for EGFR Exon 20…

Nicolas Girard, MD

NED

KEYNOTE-671

ESMO 2023

Perioperativ immunotherapy for all resectable stage…

Lizza Hendriks, MD, PhD

ENG

CheckMate 816, CheckMate 77T, ALINA, PAPILLON, MARIPOSA, MARIPOSA-2

ESMO 2023

My highlights from ESMO 2023

Alfredo Addeo, MD

ENG

TROPION-Lung1

ESMO 2023

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

Noemi Reguart, MD

ENG

DeLLphi-301

ESMO 2023

Tarlatamab in SCLC

Martin Reck, MD

EBC - discussion

ENG

monarchE, Keynote-756, CheckMate 7FL

ESMO 2023

Anticipated updates and exciting new data for…

K. Gelmon, D. Lüftner, H. Rugo, S. Tolaney

ENG

Keynote-522, NeoTrip

ESMO 2023

New and better biomarkers are needed!

K. Gelmon, D. Lüftner, H. Rugo, S. Tolaney

ENG

ESMO 2023

What is your definition of triple-negative breast…

V. Müller, C. Criscitiello, V. Diéras, P. Fasching

ENG

Natalee, monarchE

ESMO 2023

Data updates for CDK4/6 inhibitors in EBC at ESMO23 -…

M. Untch, H. Rugo, G. Curigliano, F. Cardoso, A. Gennari, J. Cortes, E. Senkus-Konefka, N. Harbeck

ENG

DESTINY-Breast-01, -02, -03; IMPACT; CheckMate 7FL; KEYNOTE-756; TROPION-Breast01; BEGONIA; DESTINY-Breast 04

ESMO 2023

What was the most exciting news at ESMO23?

V. Müller, C. Criscitiello, V. Diéras, P. Fasching

EBC - 100 seconds

ENG

KEYNOTE-756, CheckMate 7FL, monarchE, KEYNOTE-522

ESMO 2023

My highlights of ESMO23 in early breast cancer

Fatima Cardoso, MD

ENG

ADAPT

ESMO 2023

Prognostic score in early HR+/HER2-BC: translational…

Nadia Harbeck, MD, PhD

ENG

monarchE, KEYNOTE-522, KEYNOTE-756, CheckMate 7FL

ESMO 2023

Highlights in eBC

Giuseppe Curigliano, MD

ENG

ESMO 2023

ER-low corresponds diagnostically to ER-0 breast cancer

Andreas Schneeweiss, MD

ENG

monarchE

ESMO 2023

5 year follow-up

Nadia Harbeck, MD, PhD

ENG

Keynote-756, CheckMate 7FL

ESMO 2023

Neoadjuvant IO - is their new strategy in HR+ breast…

Karen Gelmon, MD

ENG

KEYNOTE-756; CheckMate 7FL

ESMO 2023

Use of immunotherapy in the perioperative setting of…

Alessandra Gennari, MD; Valentina Guarneri, MD

ENG

Keynote-522

ESMO 2023

Clinically relevant effect of pembro also in PCR

Diana Lüftner, MD

ENG

Keynote-756, CheckMate 7FL

ESMO 2023

New data on neoadjuvant immunotherapy

Véronique Diéras, MD

USA

Keynote-522

ESMO 2023

Pembrolizumab solidifies as SOC in early-stage TNBC

Hope Rugo, MD

ENG

NATALEE

ESMO 2023

Ribociclib effective in all subtypes

Andreas Schneeweiss, MD

ENG

MonarchE

ESMO 2023

MonarchE - trial update

Véronique Diéras, MD

ENG

MonarchE, KEYNOTE-522

ESMO 2023

Consolidation of data in early HR+ and triple-negative…

Michael Untch, MD

USA

CheckMate 7FL

ESMO 2023

Preoperative checkpointinihition in ER+ disease

Sara Tolaney, MD

ENG

NeoMET

ESMO 2023

Metabolomics reveal differential expression of OMEGA 3…

Alessandra Gennari, MD

ENG

monarchE

ESMO 2023

Carry-over effects in monarchE confirmed

Diana Lüftner, MD

ENG

ESMO 2023

Analysis of tumour microenvironment and…

Nadia Harbeck, MD, PhD

ENG

NATALEE

ESMO 2023

Detailed view of nodal-negative patients

Peter Fasching, MD

ENG

monarchE, KEYNOTE-522, Destiny-Breast 04

ESMO 2023

Our guidelines are correct

Karen Gelmon, MD

ENG

KEYNOTE-522

ESMO 2023

Immunoncology in eBC - triple negative and more?

Wolfgang Janni, MD

ENG

KEYNOTE-756, KEYNOTE-522

ESMO 2023

HR+ study with > 20 % PCR

Peter Fasching, MD

ENG

NeoTrip

ESMO 2023

Negative EFS results from NeoTrip

Carmen Criscitiello, MD

EBC - 100 seconds multi language

ITA

monarchE, KEYNOTE-522, KEYNOTE-756, CheckMate 7FL

ESMO 2023

Punti salienti in eBC

Giuseppe Curigliano, MD

ITA

NeoMET

ESMO 2023

La Metabolomica svela l’importanza di OMEGA 3 & OMEGA 6…

Alessandra Gennari, MD

ITA

NeoTrip

ESMO 2023

Studio NeoTrip: negativi i risultati

Carmen Criscitiello, MD

FRA

Keynote-756, CheckMate 7FL

ESMO 2023

Nouvelles données sur l'immunothérapie néoadjuvante

Véronique Diéras, MD

FRA

MonarchE

ESMO 2023

MonarchE - mise à jour de l'essai

Véronique Diéras, MD

MBC - discussion

ENG

TROPION-01 BREAST

ESMO 2023

New ADC for metastatic breast cancer?

M. Untch, H. Rugo, G. Curigliano, F. Cardoso, A. Gennari, J. Cortes, E. Senkus-Konefka, N. Harbeck

ENG

IMPACT

ESMO 2023

Improvement of therapy outcome by app-based patient…

A. Gennari, V. Dieras, B. Pistilli, V. Müller, W. Janni

DESTINY-Breast-01, -02, -03; IMPACT; CheckMate 7FL; KEYNOTE-756; TROPION-Breast01; BEGONIA; DESTINY-Breast 04

ESMO 2023

What was the most exciting news at ESMO23?

V. Müller, C. Criscitiello, V. Diéras, P. Fasching

ENG

SOLTI-1903 HOPE

ESMO 2023

How to organize a molecular tumorboards in breast…

A. Gennari, V. Dieras, B. Pistilli, V. Müller, H. Rugo

HS20089

ESMO 2023

New targets, new linker, new ADCs - much more to learn…

V. Müller, C. Criscitiello, V. Diéras, P. Fasching

ENG

DESTINY Breast -01, -02, -03, TULIP, DESTINY Breast 04, BEGONIA

ESMO 2023

ADCs in HER2+, HER2low and TNBC - what is the future of…

A. Gennari, V. Dieras, B. Pistilli, V. Müller, W. Janni

MBC - 100 seconds

ENG

PHERgain

ESMO 2023

TROP2 expression as a potential mechanism of resistance…

Javier Cortes, MD

ENG

TROPION-Breast-01

ESMO 2023

Dato-DXd - new player in advanced luminal disease

Elzbieta Senkus-Konefka, MD

ENG

TULIP

ESMO 2023

TULIP: Trastuzumab duocarmazine without OS benefit

Volkmar Müller, MD

USA

TROPiON-Breast01

ESMO 2023

New ADC in HR+ disease

Sara Tolaney, MD

ENG

Destiny Breast 04

ESMO 2023

Still on track for success in HER2-low MBC

Wolfgang Janni, MD

USA

DESTINY-Breast-01, -02, -03

ESMO 2023

Remarkable efficacies in patients with HER2+ mBC with…

Hope Rugo, MD

ENG

BEGONIA

ESMO 2023

Duvalumab + Dato-DXd effective

Andreas Schneeweiss, MD

ENG

SOLTI-1903 HOPE

ESMO 2023

Patient-centered molecular medicine - a new approach

Volkmar Müller, MD

ENG

PHERgain

ESMO 2023

HER2DX in the PHERgain trial

Javier Cortes, MD

ENG

BEGONIA, TROPION-01 Breast

ESMO 2023

DATO-DX - where is it going?

Karen Gelmon, MD

ENG

DESTINY Breast -01, -02, -03

ESMO 2023

T-DXd also effective for brain metastases

Wolfgang Janni, MD

ENG

monarchE

ESMO 2023

Robust data from the monarchE

Wolfgang Janni, MD

ENG

BEGONIA

ESMO 2023

ADC + Immunotherapy - the BEGONIA study paradigm

Barbara Pistilli, MD

ENG

IMPACT

ESMO 2023

Improved oncological therapy with the smartphone

Wolfgang Janni, MD

ENG

TROPION-Breast01, DESTINY-Breast-01, -02, 03, IMPACT

ESMO 2023

My highlights of ESMO23 in metastatic breast cancer

Fatima Cardoso, MD

ENG

HS-20089

ESMO 2023

HS20089 - a novel ADC is coming for TNBC

Carmen Criscitiello, MD

ENG

ESMO 2023

OP-1250 (Palezestrant) confirms the role of SIRDs after…

Alessandra Gennari, MD

ENG

DESTINY-breast 1, 2, 3

ESMO 2023

T-DXd in HER2+ patients with brain metastases

Volkmar Müller, MD

ENG

TROPiCS-02

ESMO 2023

Benefit for SG even after intensive pretreatment

Volkmar Müller, MD

ENG

ESMO 2023

OP seems to be dispensable for super responders

Andreas Schneeweiss, MD

ENG

FALCON

ESMO 2023

Fulvestran better than anastrozole, but no survival…

Andreas Schneeweiss, MD

ENG

DESTINY-Breast-01, -02, -03

ESMO 2023

T-DXd - new standard of care for brain mets?

Elzbieta Senkus-Konefka, MD

ENG

DESTINY-Breast 04, HS-20089, TROPION-Breast01, DESTINY-Breast-01, -02, 03

ESMO 2023

Highlights in mBC

Giuseppe Curigliano, MD

ENG

monarchE, KEYNOTE-522, Destiny-Breast 04

ESMO 2023

Our guidelines are correct

Karen Gelmon, MD

ENG

ESMO 2023

Can surgery be spared following primary systemic…

Elzbieta Senkus-Konefka, MD

ENG

monarchE

ESMO 2023

Abemaciclib remains consistent in 5-year follow-up

Peter Fasching, MD

ENG

BEGONIA

ESMO 2023

Even more new generation ADCs in breast cancer?

Wolfgang Janni, MD

MBC - 100 seconds multi language

ITA

BEGONIA

ESMO 2023

Lo studio BEGONIA nelle paziento con tumore triplo…

Barbara Pistilli, MD

POL

DESTINY-Breast-01, -02, -03

ESMO 2023

T-DXd - nowy standard postępowania w przerzutach do…

Elzbieta Senkus-Konefka, MD

FRA

BEGONIA

ESMO 2023

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par…

Barara Pistilli, MD

ITA

DESTINY-Breast 04, HS-20089, TROPION-Breast01, DESTINY-Breast-01, -02, 03

ESMO 2023

Punti salienti in mBC

Giuseppe Curigliano, MD

ESP

PHERgain

ESMO 2023

La expresión de TROP2 como potencial mecanismo de…

Javier Cortes, MD

ESP

PHERgain

ESMO 2023

HER2DX en el estudio PHERgain

Javier Cortes, MD

POL

TROPION-Breast-01

ESMO 2023

Dato-DXd - nowy gracz w zaawansowanym raku luminalnym

Elzbieta Senkus-Konefka, MD

POL

ESMO 2023

Czy możliwa jest rezygnacja z chirurgii po indukcyjnym…

Elzbieta Senkus-Konefka, MD

ITA

ESMO 2023

OP-1250 (Palezestrant) ulteriore conferma del ruolo dei…

Alessandra Gennari, MD

ITA

HS-20089

ESMO 2023

HS20089 - un nuovo ADC che si affaccia sulla scenda del…

Carmen Criscitiello, MD

Prostate cancer - discussions

ENG

PSMAfore, ENZA-p

ESMO 2023

Targeted therapy will move forward - but more robust…

O. Grimm, G. Morgan, A. Bjartell, D. Murphy, N. Shore, E. Efstathiou, S. Chowdhury

ENG

RADICALS RT, EMBARK

ESMO 2023

The optimal timing of RT after radical prostatectomy…

A. Merseburger, G. Morgan, A. Bjartell, D. Murphy, N. Shore, E. Efstathiou, S. Chowdhury

ENG

STAMPEDE

ESMO 2023

Should we use zoledronic acid in all ADT patients?

A. Merseburger, A. Bjartell, S. Chowdhury, V. Grünwald

ENG

KEYNOTE-641, KEYNOTE-991, AMG509

ESMO 2023

What is the future of immune therapy in prostate…

O. Grimm, D. Murphy, N. Shore, E. Efstathiou, S. Chowdhury, V. Grünwald

Prostate cancer - 100 seconds

ENG

EMBARK

ESMO 2023

EMBARK - Quality of Life

Anders Bjartell, MD

ENG

ESMO 2023

Big data and AI prediction tools

Anders Bjartell, MD

USA

PSMAfore

ESMO 2023

PSMA FORE: Trial and controversies

Gil Morgan, MD

AUS

EMBARK

ESMO 2023

Embark without fear

Declan Murphy, MD

ENG

RADICALS RT

ESMO 2023

Longterm toxicity of adjuvant RT after prostatectomy

Marc-Oliver Grimm, MD

ENG

KEYNOTE-461, KEYNOTE-991

ESMO 2023

IO therapy in metastatic prostate cancer.

Axel S. Merseburger, MD

ENG

ENZA-p

ESMO 2023

Combination of radioligand therapy with chemotherapy…

Axel S. Merseburger, MD

ENG

KEYNOTE-641, KEYNOTE-991

ESMO 2023

Immunotherapy in metastatic PCa

Anders Bjartell, MD

ENG

STAMPEDE

ESMO 2023

STAMPEDE. Bone prediction not for everyone - better…

Anders Bjartell, MD

ENG

KEYNOTE-641; KEYNOTE-991

ESMO 2023

When immunotherapy is probably not the best choice: The…

Ignacio Duran, MD

ENG

KEYNOTE-641, KEYNOTE-991

ESMO 2023

Negative data for pembrolizumab in mHSCPC & mCRPC

Marc-Oliver Grimm, MD

ENG

EMBARK

ESMO 2023

EMBARK expands ENZA indication to PCa

Neal Shore, MD

ENG

EMBARK

ESMO 2023

Early use of enzalutamide in advanced prostate cancer

Axel S. Merseburger, MD

ENG

STAMPEDE

ESMO 2023

Osteoprotection at mHSPC

Axel S. Merseburger, MD

ENG

CXCR2-inhbitors

ESMO 2023

CXCR2 inhibitor in PCa

Anders Bjartell, MD

ENG

RADICALS RT

ESMO 2023

Salvage radiotherapy the new standard

Axel S. Merseburger, MD

ENG

PSAMfore

ESMO 2023

PSMAfore unleashes urooncologic opportunity

Neal Shore, MD

ENG

TITAN

ESMO 2023

TITAN: ultra-low PSA = best prognosis

Axel S. Merseburger, MD

USA

RADICALS RT

ESMO 2023

RADICALS RT: Trial and controversies

Gil Morgan, MD

ENG

AMG509

ESMO 2023

Brave New World in mCRPC

Philipp Ivanyi, MD

ENG

MAGNITUDE

ESMO 2023

Precision medicine at mCRCP

Axel S. Merseburger, MD

USA

ENZA-p

ESMO 2023

ENZA P:Trial and controversies

Gil Morgan, MD

AUS

PSMAfore, ENZA-p

ESMO 2023

Lu-PSMA leads forward

Declan Murphy, MD

Prostate cancer - 100 seconds multi language

SWE

CXCR2-inhbitors

ESMO 2023

CXCR2 hämmare och prostatacancer

Anders Bjartell, MD

ESP

KEYNOTE-641; KEYNOTE-991

ESMO 2023

Cuando la inmunoterapia probablemente no es la mejor…

Ignacio Duran, MD

SWE

STAMPEDE

ESMO 2023

STAMPEDE data. Skelettstärkande och riskstratifiering.

Anders Bjartell, MD

SWE

EMBARK

ESMO 2023

EMBARK och livskvalitet

Anders Bjartell, MD

SWE

KEYNOTE-641, KEYNOTE-991

ESMO 2023

Immunterapi vid prostatacancer

Anders Bjartell, MD

SWE

ESMO 2023

Big Data och AI för prediktion vid prostatacancer

Anders Bjartell, MD

Bladder cancer - Discussions

ENG

CheckMate 901

ESMO 2023

Part1: New standard of care in first line urothelial…

L.-M. Krabbe, I. Duran, S. Chowdhury, Y. Loriot, T. Powles, J. Bellmunt, P. Grivas, V. Grünwald

ENG

EV-302/KeynoteA38

ESMO 2023

Part 2: New standard of care in first line urothelial…

L.-M. Krabbe, I. Duran, S. Chowdhury, Y. Loriot, T. Powles, J. Bellmunt, P. Grivas, V. Grünwald

ENG

THOR-2, DAD

ESMO 2023

FGFR inhibitors and ADC combinations in urothelial…

M.-O. Grimm, I. Duran, S. Chowdhury, J. Bellmunt, Y. Loriot, P. Grivas

Bladder cancer - 100 seconds

ENG

THOR; THOR-2

ESMO 2023

FGFR inhibitors: What is the best scenario for this…

Ignacio Duran, MD

ENG

CheckMate 901

ESMO 2023

Chemo-IO establishes itself in the first-line treatment…

Viktor Grünwald, MD

ENG

EV-302/KEYNOTE-A39, CheckMate-901

ESMO 2023

New SoC in firstline bladder cancer

Philipp Ivanyi, MD

ENG

EV-302/KEYNOTE-A39

ESMO 2023

When the history of ADC is written: Redefining…

Ignacio Duran, MD

USA

DAD

ESMO 2023

DAD, DAD-IO

Sumanta K. Pal, MD

ENG

TSA-200

ESMO 2023

Unique bladder delivery system of gemcitabine herolds…

Neal Shore, MD

ENG

THOR; THOR-2; EV-302/KEYNOTE-A39; CheckMate 901

ESMO 2023

Amazing new data in bladder cancer

Petros Grivas, MD

ENG

EV-302/KEYNOTE-A39

ESMO 2023

EV + Pembro as standard of care in first-line therapy…

Viktor Grünwald, MD

ENG

THOR, THOR-2

ESMO 2023

The FGFR story in bladder cancer at ESMO23

Yohann Loriot, MD

Bladder cancer - 100 seconds multi language

FRA

THOR, THOR-2

ESMO 2023

L'histoire du FGFR dans le cancer de la vessie à…

Yohann Loriot, MD

ESP

EV-302/KEYNOTE-A39

ESMO 2023

Reescribiendo la historia de una enfermedad: Nuevo…

Ignacio Duran, MD

ESP

THOR; THOR-2

ESMO 2023

Inhibidores de FGFR: Cual es el mejor escenario para…

Ignacio Duran, MD

GRE

THOR; THOR-2; EV-302/KEYNOTE-A39; CheckMate 901; LITESPARK-003; LITESPARK-005; RENOTORCH

ESMO 2023

Στιγμιότυπα για τον καρκίνο των νεφρών και της…

Petros Grivas, MD

Kidney cancer - Discussions

ENG

MEDI5752

ESMO 2023

Where does the future therapy go in renal cell…

P. Ivanyi, H. Hammers, J. Bellmunt, I. Duran, S. Chowdhury, T. Powles, M. Pal

ENG

LITESPARK-005

ESMO 2023

Important new treatment option but only for subset of…

P. Ivanyi, H. Hammers, J. Bellmunt, I. Duran, S. Chowdhury, T. Powles, M. Pal

ENG

TIDE-A

ESMO 2023

Is de-escalating therapy ready for prime-time?

P. Ivanyi, H. Hammers, J. Bellmunt, I. Duran, S. Chowdhury, T. Powles, M. Pal

Kidney cancer - 100 seconds

ENG

LITESPARK-003, LITESPARK-005, LITESPARK-013

ESMO 2023

New mode of action in mRCC - ready for prime time?

Philipp Ivanyi, MD

ENG

LITESPARK-005

ESMO 2023

New 3rd line therapy for RCC

Marc-Oliver Grimm, MD

USA

RENOTORCH

ESMO 2023

Clearing up non-clear cell RCC

Sumanta K. Pal, MD

USA

LITESPARK-03, LITESPARK-05

ESMO 2023

Belzutifan - whats next kidney cancer?

Sumanta K. Pal, MD

ENG

TIDE-A

ESMO 2023

Intermittent therapy also possible with TKIs

Viktor Grünwald, MD

ENG

LITESPARK-003; LITESPARK-005; RENOTORCH

ESMO 2023

Kidney cancer highlights at ESMO23

Petros Grivas, MD

ENG

LITESPARK-005

ESMO 2023

Belzutifan in later lines of therapy

Viktor Grünwald, MD

Discussions

ALINA

ESMO 2023

ALINA - remarkably positive DFS in early-stage ALK+…

M. Thomas, D. Tan, N. Reguart, M. Reck, S. Liu, N. Girard

CheckMate 816; Keynote-671; CheckMate 77T

ESMO 2023

Moving patients to the neoadjuvant setting in…

F. Griesinger, M. Thomas, A. Addeo, R. Shah, L. Hendricks, D. Moro-Sibilot

NSCLC early stages - 100 seconds

ENG

KEYNOTE-671, CheckMate 77T

ESMO 2023

Scene is set for inductive immunotherapy

Michael Thomas, MD

ENG

ALINA

ESMO 2023

Substantial improvement in local regional NSCLC

Michael Thomas, MD

ENG

ALINA

ESMO 2023

Adjuvant alectinib in patients with early-stage ALK+…

Frank Griesinger, MD, PhD

ENG

KEYNOTE-671

ESMO 2023

Perioperative IO: OS-benefi from KEYNOTE-671

Nicolas Girard, MD

ENG

ALINA

ESMO 2023

ALINA - a new paradigm in operated NSCLC with…

Denis Moro-Sibilot, MD

ENG

CheckMate 816, CheckMate 77T, ALINA, PAPILLON, MARIPOSA, MARIPOSA-2

ESMO 2023

My highlights from ESMO 2023

Alfredo Addeo, MD

ENG

AEGEAN

ESMO 2023

Circulating DNA in AEGEAN trial

Martin Reck, MD

ENG

KEYNOTE-671, CheckMate 77T, CheckMate 816

ESMO 2023

Neoadjuvant chemo-immunotherapy new standards in early…

Frank Griesinger, MD, PhD

NED

KEYNOTE-671

ESMO 2023

Perioperativ immunotherapy for all resectable stage…

Lizza Hendriks, MD, PhD

USA

ALINA

ESMO 2023

ALINA - immediate change of practice!

Stephen Liu, MD

ENG

KEYNOTE-671; CheckMate 77T; ALINA; LIBRETTO-431

ESMO 2023

Big improvements in early stage and a subset of…

Denis Moro-Sibilot, MD

NSCLC early stages - 100 seconds multi language

ITA

CheckMate 816, CheckMate 77T, ALINA, PAPILLON, MARIPOSA, MARIPOSA-2

ESMO 2023

I miei punti salienti di ESMO 2023

Alfredo Addeo, MD

FRA

KEYNOTE-671; CheckMate 77T; ALINA; LIBRETTO-431

ESMO 2023

Gros progrès dans les traitments medicaeux des stades…

Denis Moro-Sibilot, MD

NED

KEYNOTE-671

ESMO 2023

Perioperatieve chemo-immunotherapie voor alle patienten…

Lizza Hendriks, MD, PhD

FRA

ALINA

ESMO 2023

ALINA - un nouveau paradigme dans cBNPC avec la fusion…

Denis Moro-Sibilot, MD

FRA

CheckMate 816, CheckMate 77T, ALINA, PAPILLON, MARIPOSA, MARIPOSA-2

ESMO 2023

Les points forts de l'ESMO 2023

Alfredo Addeo, MD

Discussions

PAPILLON; LIBRETTO-431

ESMO 2023

Rare oncogenic alterations: landmark results on exon 20…

M. Thomas, D. Tan, N. Reguart, M. Reck, S. Liu, N. Girard

ENG

TROPION-Lung01, TROPION-Lung05

ESMO 2023

Evolving landscape of ADCs

N. Reguart, L.Hendriks, M. Reck, M. Thomas, S. Liu, N. Girard, D. Moro-Sibilot, D. S.W. Tan, S. Rothschild

ENG

MARIPOSA, MARIPOSA-2, PAPILLON, FLAURA2

ESMO 2023

Activating EGFR-mutation - what's coming up?

N. Reguart, L.Hendriks, M. Reck, M. Thomas, S. Liu, N. Girard, D. Moro-Sibilot, D. S.W. Tan, S. Rothschild

ESMO 2023

ESMO2023-impact on everyday practice!

F. Griesinger, M. Thomas, A. Addeo, R. Shah, L. Hendricks, D. Moro-Sibilot

NSCLC adv/met - 100 seconds

ENG

ESMO 2023

NRG fusions: a new drugable target?

Riyaz Shah, MD

ENG

MARIPOSA ,MARIPOSA-2

ESMO 2023

Treatment sequences for EGFR-mutated Patients

Nicolas Girard, MD

ENG

LIBRETTO-431, PAPILLON

ESMO 2023

Substantial improvement in rare alterations

Michael Thomas, MD

ENG

FLAURA-2, HERTHENA-Lung01, TROPION-Lung05

ESMO 2023

Brain metastases – options to improve the systemic…

Michael Thomas, MD

ENG

PAPILLON

ESMO 2023

Amivantamab as a new SoC for EGFR Exon 20…

Nicolas Girard, MD

USA

SAPPHIRE

ESMO 2023

By unanimous decision and still the champion –…

Hossein Borghaei, MD

USA

MARIPOSA II

ESMO 2023

MARIPOSA II: Trial and controversies

Gil Morgan, MD

ENG

ATTLAS

ESMO 2023

Does immunotherapy still have a place in EGFR-positive…

Lizza Hendriks, MD, PhD

ENG

LIBRETTO-431

ESMO 2023

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

Frank Griesinger, MD, PhD

ENG

TROPION-Lung1

ESMO 2023

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

Noemi Reguart, MD

ENG

KRYSTAL-7

ESMO 2023

Adagrasib + pembrolizumab in patients with KRASG12C…

Martin Reck, MD

ENG

MARIPOSA; MARIPOSA-2

ENMO 2023

Changing treatment landscape in EGFR-mutated NSCLC

Sacha Rothschild, MD

ENG

MARIPOSA-2

ESMO 2023

Amivantamab at progression? MARIPOSA-2 trial

Noemi Reguart, MD

ENG

MARIPOSA

ESMO 2023

Amivantamab upfront? MARIPOSA trial

Noemi Reguart, MD

USA

LIBRETTO-431

ESMO 2023

LIBRETO - a positive study, but was it necessary?

Stephen Liu, MD

ENG

HERTHENA-Lung01

ESMO 2023

Do ADCs have brain activity?

Riyaz Shah, MD

ENG

PAPILLON

ESMO 2023

New standard of care for metastatic EGFR exon 20…

Lizza Hendriks, MD, PhD

ENG

PAPILLON

ESMO 2023

Practice changing results on exon 20 insertion mNSCLC

Frank Griesinger, MD, PhD

USA

MARIPOSA

ESMO 2023

MARIPOSA: Trial and controversies

Gil Morgan, MD

USA

TROPION-Lung01

ESMO 2023

TROPION-Lung01: positive development

Hossein Borghaei, MD

ENG

KEYNOTE-671; CheckMate 77T; ALINA; LIBRETTO-431

ESMO 2023

Big improvements in early stage and a subset of…

Denis Moro-Sibilot, MD

ENG

PAPILLON

ESMO 2023

PAPILLON - bringing together therapy for the 1st line

Stephen Liu, MD

ENG

CheckMate 816, CheckMate 77T, ALINA, PAPILLON, MARIPOSA, MARIPOSA-2

ESMO 2023

My highlights from ESMO 2023

Alfredo Addeo, MD

NSCLC adv/met - 100 seconds multi language

FRA

KEYNOTE-671; CheckMate 77T; ALINA; LIBRETTO-431

ESMO 2023

Gros progrès dans les traitments medicaeux des stades…

Denis Moro-Sibilot, MD

FRA

PAPILLON

ESMO 2023

L’amivantamab, nouveau standard de traitement pour les…

Nicolas Girard, MD

ESP

MARIPOSA-2

ESMO 2023

Amivantamab at progression? MARIPOSA-2 trial

Noemi Reguart, MD

FRA

MARIPOSA, MARIPOSA-2

ESMO 2023

Quelles séquences thérapeutiques pour les patients EGFR…

Nicolas Girard, MD

ESP

MARIPOSA

ESMO 2023

Amivantamab upfront? MARIPOSA trial

Noemi Reguart, MD

ITA

CheckMate 816, CheckMate 77T, ALINA, PAPILLON, MARIPOSA, MARIPOSA-2

ESMO 2023

I miei punti salienti di ESMO 2023

Alfredo Addeo, MD

ESP

TROPION-Lung1

ESMO 2023

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

Noemi Reguart, MD

FRA

CheckMate 816, CheckMate 77T, ALINA, PAPILLON, MARIPOSA, MARIPOSA-2

ESMO 2023

Les points forts de l'ESMO 2023

Alfredo Addeo, MD

NED

PAPILLON

ESMO 2023

Nieuwe standaard voor gemetastaseerd EGFR exon20…

Lizza Hendriks, MD, PhD

SUI

MARIPOSA; MARIPOSA-2

ESMO 2023

Veränderte Behandlungslandschaft bei EGFR-mutiertem…

Sacha Rothschild, MD

NED

ATTLAS

ESMO 2023

Heeft immunotherapie nog een plek in de behandeling van…

Lizza Hendriks, MD, PhD

Discussions

ENG

DeLLphi-301, TROPiCS-03

ESMO 2023

Impact of T-cell engagers in SCLC

N. Reguart, L.Hendriks, M. Reck, M. Thomas, S. Liu, N. Girard, D. Moro-Sibilot, D. S.W. Tan

SCLC - 100 seconds

ENG

DeLLphi-301

ESMO 2023

Tarlatamab in SCLC

Martin Reck, MD

ENG

DeLLphi-301

ESMO 2023

A new option in relapsed SCLC

Riyaz Shah, MD

ENG

DeLLphi-301

ESMO 2023

New hope for patients with SCLC

Sacha Rothschild, MD

SCLC - 100 seconds multi language

SUI

DeLLphi-301

ESMO 2023

Neue Hoffnung für Patienten mit SCLC

Sacha Rothschild, MD

Varia - 100 seconds

ENG

CUPISCO, CUP-ONE

ESMO 2023

Precision oncology in CUP

Philipp Ivanyi, MD

ENG

FLAMES

ESMO 2023

Update on gynaecological cancers

Michael Untch, MD

ENG

RUBY

ESMO 2023

Evolution of the revolution - the RUBY trial

Diana Lüftner, MD

ENG

ESMO 2023

PCO Therapeutics

Philipp Ivanyi, MD

ENG

ESMO 2023

First data on luveltamab in multiline treatment for…

Diana Lüftner, MD

ENG

MEDISARC; TOMAS2

ESMO 2023

New data on sarkomas

Philipp Ivanyi, MD

ENG

OMET; INTERLINK-1

ESMO 2023

New data on H&N Cancer

Philipp Ivanyi, MD